Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS

NCT05266001 is registered in ClinicalTrials.gov with Nationwide Children's Hospital as lead sponsor.

NCT NCT05266001
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05266001 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GM-CSF for Reversal of Immunoparalysis in Pediatric Sepsis-induced MODS
Lead sponsor
Nationwide Children's Hospital
Phase
Phase 3
Overall status
Completed
Start date
June 14, 2022
Completion date
September 10, 2025
Enrollment
141 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

pediatric sepsis-induced multiple organ dysfunction syndrome